December 19th 2025
Your daily dose of the clinical news you may have missed.
December 15th 2025
The mobile-based program targets cognitive processes underlying attention and is intended for use alongside medication, therapy, or education.
Missed endpoints in midstage tau trials are reshaping the Alzheimer pipeline, with growing focus on inflammatory and vascular pathways. Review them here.
December 12th 2025
A population-based study finds stimulant prescribing accelerated after 2020, with the largest increases among adults and women.
A new review examines whether neuromodulation techniques may help address excessive daytime sleepiness across neurologic and psychiatric conditions.
Donanemab Treatment Linked to Increase Risk of Serious ARIA in Alzheimer Disease
Analysis of data from the donanemab TRAILBLAZER development program underscores the essential role of patient selection and treatment monitoring.
First Rivaroxaban Generics (2.5 mg) Get FDA Approval
The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.
FDA Pre-NDA Meeting for AXS-05 in Alzheimer's Disease Sets Stage for sNDA Submission in Q3 2025
Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.
Nonopioid Analgesic Pilavapadin Advances to Phase 3 for Diabetic Neuropathy
The investigational once-daily oral analgesic, a potent inhibitor of a novel target for neuropathic pain, achieved meaningful pain reduction vs placebo.
FDA Greenlights New Wearable Treatment for Parkinson Disease: Daily Dose
Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents
While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.
Eli Lilly Expands Zepbound Access with New Vial Doses, Self-Pay Savings
Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.
Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial
Symbravo, compared with previous CGRP inhibitor therapy, achieved superior response across efficacy measures including pain freedom and improvements in QoL.
Obesity and Mental Health: Expert Details Interplay, How the Sexes Differ
Shagun Bindlish, MD, discusses the complex interplay between obesity and mental health conditions and how sex is a potential moderating factor.
Sinaptica Announces Enrollment for Phase 2 Clinical Trial in Early Alzheimer Disease of Dual Neuromodulation System
The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.
Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose
Overlap in Pathophysiology Suggests New Approaches to Acute Pain May Transfer to Relief from Chronic Pain: A Closer Look
Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.
New Biomarkers Identified for Early Detection of Alzheimer Disease
Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.
Heart Disease Remains Leading Cause of Death in US: Daily Dose
Suzetrigine (Journvax) Fits Neatly in a Multimodal Strategy to Manage Acute Pain, According to Edward Mariano, MD, MAS
Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.
Headaches and Suicide
The risk of a suicide attempt was 2 times greater among those with headache, across types including tension type headache, migraine, trigeminal autonomic cephalalgia, and posttraumatic headache.
Elevated Suicide Risk Identified in People with Headache Disorders
Post-traumatic headaches and trigeminal autonomic cephalalgia significantly increased the risk for attempted and completed suicide, according to new study.
Use of Perioperative Multimodal Pain Management in the US Remains Low, Expert Says
An anesthesiologist and renowned investigator in use of nonopioids as part of multimodal pain management, Edward Mariano, MD, MAS, describes slow uptake in the field.
Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain
AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.
FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose
US Dementia Cases to Double by 2060: Daily Dose
FDA Approves New Wearable Treatment for Parkinson Disease
Onapgo is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in people with advanced Parkinson disease.
Opioid Prescribing Has Come a Long Way, According to Stanford Pain Expert Edward Mariano, MD, MAS
Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.
FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose
Investigators Identify Hemoglobin A1c/HDL-C as a Predictor of Stroke Risk in Older Adults
Elevated HbA1c/HDL-C ratios significantly increased stroke risk, even after adjusting for confounding factors, reported authors of a recent study.
New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments
Pharmacologic treatment to prevent episodic migraine should follow a sequential trial approach that considers medication cost, headache triggers, adherence, and lifestyle interventions.
FDA Approves Monthly Lecanemab for Early-Stage Alzheimer Disease: Daily Dose
Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD
Tepper, principal investigator for phase 3 trials of Symbravo as acute treatment for migraine in adults, reviews the new drug's dual MOA and target patient populations.
Agitation in Alzheimer Disease: A Behavioral Snapshot with Geriatric Psychiatrist George Grossberg, MD
Agitation is the most common disabling neuropsychiatric symptom experienced by individuals with Alzheimer dementia; Grossberg explains how common in this short interview.
Global Migraine Burden Rising Fastest Among Men and Adolescents, New Research Finds
The global burden of migraine rose by 58% between 1990 and 2021 to more than 1 billion, a pace projected to continue and most rapidly among men and young people.